RxDoctor Payments Data

Klaus Werner

Neurology with Special Qualifications in Child Neurology · Syracuse, NYNPI 1871854141

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Novartis accounts for 95.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $18,684 and has fallen 99.4% since, to $119 in 2025. Among neurology with special qualifications in child neurology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,135in general payments, 2019–2025

Across 40 payments — averaging $528.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$20K
  • Lilly USA, LLC$271
  • Nobelpharma America, LLC$243
  • AbbVie$193
  • Teva Pharmaceuticals USA, Inc.$106
  • Amgen$91
  • plus $151 from 2 others
$682,216in research payments, 2019–2025

Across 281 payments — averaging $2427.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Teva Pharmaceuticals USA, Inc.$616K
  • Pfizer$66K

What the payments were for

  • Consulting fees$1,7048%
  • Speaking & faculty fees$12,35458%
  • Travel & lodging$5,61827%
  • Food & beverage$1,4597%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,135 in reported general payments places this provider in the 90th percentile of 161 neurology with special qualifications in child neurology providers in New York.

See all neurology with special qualifications in child neurology providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm13$8,636

Paid to pharmacies, not to this prescriber.

Other neurology with special qualifications in child neurology in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →